HC Wainwright Analysts Cut Earnings Estimates for Immunocore

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – Analysts at HC Wainwright cut their FY2027 earnings per share estimates for shares of Immunocore in a note issued to investors on Wednesday, March 4th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $0.84 for the year, down from their prior estimate of $0.93. HC Wainwright currently has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunocore’s FY2028 earnings at $4.07 EPS, FY2029 earnings at $7.50 EPS and FY2030 earnings at $11.20 EPS.

Other equities research analysts have also recently issued reports about the company. UBS Group set a $55.00 target price on Immunocore and gave the company a “buy” rating in a research report on Wednesday, January 7th. Needham & Company LLC boosted their price objective on Immunocore from $71.00 to $75.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Morgan Stanley increased their target price on Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Mizuho set a $38.00 price target on shares of Immunocore in a research note on Thursday, February 19th. Finally, Zacks Research cut shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Immunocore presently has a consensus rating of “Moderate Buy” and an average target price of $61.30.

Immunocore Stock Performance

Shares of NASDAQ IMCR opened at $31.93 on Thursday. Immunocore has a 1 year low of $23.15 and a 1 year high of $40.71. The company has a debt-to-equity ratio of 1.03, a quick ratio of 4.01 and a current ratio of 4.04. The company’s fifty day moving average price is $33.17 and its 200 day moving average price is $34.32. The company has a market capitalization of $1.61 billion, a PE ratio of -45.61 and a beta of 0.78.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.32). The company had revenue of $104.48 million during the quarter, compared to analyst estimates of $145.48 million. Immunocore had a negative net margin of 8.88% and a negative return on equity of 9.20%. The company’s revenue was up 24.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.47) earnings per share.

Insiders Place Their Bets

In related news, insider Leger Tina Amber St sold 1,000 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $32,350.00. Following the completion of the sale, the insider owned 1,119 shares of the company’s stock, valued at approximately $36,199.65. This represents a 47.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David M. Berman sold 5,965 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $192,967.75. Following the completion of the transaction, the insider directly owned 5,859 shares in the company, valued at $189,538.65. This trade represents a 50.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 19,137 shares of company stock valued at $619,082 in the last 90 days. 10.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Immunocore

A number of large investors have recently made changes to their positions in the stock. Leonteq Securities AG acquired a new position in Immunocore during the fourth quarter worth $30,000. GAMMA Investing LLC increased its position in Immunocore by 51.6% during the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock worth $33,000 after purchasing an additional 311 shares during the last quarter. Harbour Investments Inc. raised its stake in Immunocore by 60.2% during the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after purchasing an additional 388 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in Immunocore in the 2nd quarter valued at about $42,000. Finally, Arax Advisory Partners grew its stake in shares of Immunocore by 302.9% in the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after buying an additional 1,042 shares during the period. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.